

SALIWANCHIK, LLOYD & SALIWANCHIK A Professional Association

2421 N.W. 41st Street Suite A-1 Gainesville, FL 32606

Telephone (352) 375-8100 Facsimile (352) 372-5800 كالمرافقا المانية

FAX RECEIVED

GROUP 1600

TO:

Evaminer Marianne DiBrino

FROM:

Frank C. Eisenschenk, Ph.D.

COMPANY:

U.S. Patent Office, Art Unit 1644

DATE: March 5, 2002

FAX NO.:

1-703-308-4242

NO. OF PAGES:

NO. OF PAGES: (INCLUDING COVER SHEET)

SUBJECT/MESSAGE:

U.S. Patent Application Docket No. SPO-103

Peptide-Based Immunotherapeutic Agent for Treating Allergic

Diseases (Sone, et al.)

Serial No. 09/142,524; Filed September 9, 1998

THIS IS AN OFFICIAL DOCUMENT. PLEASE DELIVER IMMEDIATELY.

Attachment: Preliminary Amendment

The information contained in this facsimile message is intended only for the personal and confidential use of the designated recipients named above. This message may be an attorney-client communication, and as such is privileged and confidential. If the reader of this message is not the intended recipient or an agent responsible for delivering it to the intended recipient, you are hereby notified that you have received this document in error, and that any review, dissemination, distribution, or copying of this message is strictly prohibited If you have received this communication in error, please notify us immediately by telephone and return the original message by mail. Thank you.

I hereby certify that this correspondence is being facsimile transmitted to the United States Patent and Trademark Office on March 5, 2002.

Frank C. Eisenschenk, Ph.D., Patent Attornev

PRELIMINARY AMENDMENT Examining Group 1644 Patent Application Docket No. SPO-103

Serial No. 09/142,524

FAX RECEIVED

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE WAR $0.6\,$ 2017.

GROUP 1600

Examiner

M. DiBrino, Ph.D.

Art Unit

1644

Applicants

Toshio Sone, Akinori Kume, Kazuo Dairiki, Akiko Iwama, Kohsuke Kino

Serial No.

09/142,524

September 9, 1998

Filed Conf. No. For

2300

Peptide-based Immunotherapeutic Agent for Treating Allergic Diseases

Assistant Commissioner for Patents

Washington, D.C. 20231

PRELIMINARY AMENDMENT

Please amend the above-identified patent application as follows:

In the Claims

Please substitute the following claims.

Claim 1. (Thrice Amended):

A peptide-based immunotherapeutic agent for cedar pollinosis comprising a linear polypeptide molecule, wherein said polypeptide:

(a) comprises at least two T-cell epitope peptides derived from cedar pollen allergen Cry j l and at least two T-cell epitope peptides derived from cedar pollen allergen Cry i 2;

S:\SH-RESP\SPO-103-PrelimAmend.doc/DNB/jaj